Today: 9 June 2026
Reliance stock set for Monday spotlight as Jio IPO talk collides with Q3 results countdown
10 January 2026
2 mins read

Reliance stock set for Monday spotlight as Jio IPO talk collides with Q3 results countdown

Mumbai, Jan 11, 2026, 02:27 IST — Market closed

  • Reliance shares ended Friday slightly higher after a rough week, with traders turning their attention to possible catalysts expected around mid-January.
  • Reuters reported that Reliance’s Jio Platforms is mulling a small-float IPO, but only if a rule change goes through.
  • Reliance is set to release its quarterly results on Jan. 16.

Shares of Reliance Industries are likely to draw focus when Indian markets open Monday after a Reuters report said its telecom division, Jio Platforms, is planning an IPO this year. The deal would see Jio sell a 2.5% stake in the company.

Reliance shares edged up 0.34% on Friday, finishing at 1,475.30 rupees. While the BSE Sensex slipped 0.72%, the heavyweight stock bucked the downward trend as the market headed into the weekend.

Why this matters now: Reliance’s next moves are emerging as a crucial near-term indicator for investors tracking earnings season. They’re focused on whether the group can drive value through new listings and if consumer appetite holds firm in its retail business.

Reliance is set to release its quarterly earnings on Jan. 16, marking the start of a hectic week closely monitored by many investors in India for signs of broader corporate health.

Reuters reports that Reliance plans to offer just 2.5% of Jio in its IPO, reflecting the company’s enormous size. The firm is pushing for a regulatory change to slash the minimum public float for big IPOs from 5% down to 2.5%, subject to approval from the finance ministry. Valuations vary: Jefferies pegs Jio at $180 billion, while some bankers suggest a range between $200 billion and $240 billion. Reliance hasn’t settled on a final price yet.

Reliance shares have fallen about 8% from their 52-week high of 1,611.80 rupees hit on January 5. The sharp retreat is raising questions about the management’s projections for margins, demand, and capital spending.

Brokerage buzz is driving the moves. Goldman Sachs’ Nikhil Bhandari bumped his price target on Reliance to 1,835 rupees, leaving it solidly on the bank’s Conviction Buy list, according to .

Goldman expects Reliance’s retail arm to report slower earnings growth in Q3, but a boost from energy, particularly refining, should help offset some of that, according to an summary of the note.

The stock’s steep plunge early in 2026 has ramped up expectations for this earnings report to restore investor faith. Bloomberg, cited in India’s Economic Times, notes the company has lost about $15 billion in market value so far this year.

Investors are set to focus on three main areas in the near term: refining margins, which show how profitable it is to convert crude into fuels; retail growth alongside discounting strategies; and developments at Jio’s telecom division, especially any hints on pricing moves and capital spending amid intensifying competition.

Competitive pressures are clear. Valuing Jio inevitably pulls Bharti Airtel into the discussion as a key listed rival. Reuters also pointed to Jio’s move into AI infrastructure and the emerging threat Starlink poses to India’s broadband market.

But the IPO plan depends on one big “if.” If the rule change hits a snag or markets turn choppy, Reliance could delay or scale back the offering. That would put more pressure on retail demand and the energy sector’s momentum to drive the stock higher.

Reliance’s board will meet on Jan. 16 to review and approve its quarterly and nine-month results, then hold a session with analysts.

Stock Market Today

  • Pro Portfolio Adds Broadcom and Netflix Shares, Upgrades Broadcom Rating
    June 9, 2026, 10:19 AM EDT. The Pro Portfolio is buying 80 shares of Broadcom (AVGO) at around $405, increasing its holdings to 512 shares (3.4% of the portfolio). It is also purchasing 372 shares of Netflix (NFLX) near $82.35, increasing its stake to 2,107 shares (2.85%). Broadcom's AI chip forecast for H2 2026 is viewed as conservative following a $35 billion private credit deal involving Apollo and Blackstone. The rating for Broadcom is upgraded to One, with a checkpoint price of $330 maintained. Netflix's shares are seen as undervalued despite recent declines, supported by a $25 billion buyback and rising U.S. viewership. Netflix's ad business shows growth potential, reaching 250 million monthly active viewers, reinforcing optimism amidst concerns over consumer spending.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Why Kweichow Moutai Co., Ltd. Class A stock (600519) is in focus: iMoutai restock and a fresh target cut
Previous Story

Why Kweichow Moutai Co., Ltd. Class A stock (600519) is in focus: iMoutai restock and a fresh target cut

BigBear.ai stock (BBAI) eyes Monday open after Kraft Group, Patriots tie-up; share vote looms
Next Story

BigBear.ai stock (BBAI) eyes Monday open after Kraft Group, Patriots tie-up; share vote looms

Go toTop